Gut Microbiome Changes in Heart Failure from Doxorubicin
Author Information
Author(s): Wang Qian, Liu Meihua, Liu Tianpei, Li Long, Wang Chenyang, Wang Xiaolin, Rong Shuling, Zhou Xuedong
Primary Institution: The Second Hospital of Shanxi Medical University
Hypothesis
This study aimed to explore the changes in gut microbiota and its metabolites in different pathophysiological stages of doxorubicin-induced heart failure (DIHF) and the relationship between gut microbiota and metabolites in various degrees of DIHF.
Conclusion
Marked differences were found in the composition and abundance of gut microorganisms, the levels of serum metabolites, and metabolic pathways in different degrees of DIHF.
Supporting Evidence
- Doxorubicin caused cardiac contractile dysfunction and left ventricular dilation.
- The levels of myocardial enzymes significantly increased after doxorubicin treatment.
- Gut microbiota composition changed significantly with the severity of heart failure.
Takeaway
This study looked at how a medicine called doxorubicin affects the tiny bugs in our stomachs and how these changes relate to heart problems.
Methodology
C57BL/6J mice were injected with doxorubicin, and their cardiac function and gut microbiota were analyzed using echocardiography and 16S rRNA gene sequencing.
Limitations
The study was conducted on mice, which may not fully represent human responses.
Participant Demographics
Healthy male C57BL/6J mice, aged 8 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website